Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

BTC health Limited

ABN 45 091 979 172

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 ⁺Class of ⁺securities issued or to be issued (1) Ordinary Shares(2) Unlisted Options

(1) 67,533,874

(2) 5,000,000

- 2 Number of *securities issued or to be issued (if known) or maximum number which may be issued
- 3 Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

• • •		d Ordinary S exercisable		expiring
	21 June	2022		

⁺ See chapter 19 for defined terms.

4	 Do the ⁺securities rank equally in all respects from the ⁺issue date with an existing ⁺class of quoted ⁺securities? If the additional ⁺securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	 (1) Yes, shares rank equally with all other issued shares, including for dividends. (2) No – Upon exercise of options, securities will rank equally with existing fully paid ordinary shares.
5	Issue price or consideration	(1) \$0.08 (2) Nil
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	 (1) Fully paid ordinary shares issued pursuant to the companies notice of Extraordinary General Meeting dated 21 June 2019 (2) Options issued pursuant to the Company's notice of Extraordinary General Meeting dated 21 June 2019.
6a	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the ⁺securities the</i> <i>subject of this Appendix 3B</i> , and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	28/11/2018
6c	Number of +securities issued without security holder approval under rule 7.1	Nil
6d	Number of +securities issued with security holder approval under rule 7.1A	Nil

6e	Number of ⁺ securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	(1) Nil (2) 5,000,000 a meeting 21	at the extraordinary general June 2019.
6f	Number of ⁺ securities issued under an exception in rule 7.2	(1) 67,533,874 (2) Nil	
6g	If ⁺ securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the ⁺ issue date and both values. Include the source of the VWAP calculation.	Not applicable	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	Not applicable	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Remaining capacity 36,681,417 Remaining capacity 24,454,278	
7	⁺ Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.	(1) 27 June 2019 (2) 21 June 2019	
	cross reference. Item 55 of Appendix 55.	Number	+Class
8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in section 2 if applicable)	244,542,783	Ordinary Shares

⁺ See chapter 19 for defined terms.

		Number	+Class
9	Number and ⁺ class of all ⁺ securities not quoted on ASX (<i>including</i> the ⁺ securities in section 2 if applicable)	7,500,000	Unlisted Options
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Unchanged	

Part 2 - Pro rata issue

11	Is security holder approval required?	Not applicable
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the ⁺ securities will be offered	
14	⁺ Class of ⁺ securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

or commission

20

21

22

23 Fee or commission payable to the broker to the issue

Names of any underwriters

Amount of any underwriting fee

Names of any brokers to the issue

- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
- 25 If the issue is contingent on security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and offer documents will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do security holders sell their entitlements *in full* through a broker?
- 31 How do security holders sell *part* of their entitlements through a broker and accept for the balance?




eir a

Appendix 3B Page 5

⁺ See chapter 19 for defined terms.

- 32 How do security holders dispose of their entitlements (except by sale through a broker)?
- 33 ⁺Issue date



Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of ⁺securities (*tick one*)
 - +Securities described in Part 1



(a)

All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36 If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories

1 - 1,000
1,001 - 5,000
5,001 - 10,000
100,001 and over

37 A copy of any trust deed for the additional *securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of ⁺ securities for which ⁺ quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought		
40	Do the ⁺ securities rank equally in all respects from the ⁺ issue date with an existing ⁺ class of quoted ⁺ securities?		
	 If the additional ⁺securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another ⁺ security, clearly identify that other ⁺ security)		
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)	Number	+Class

⁺ See chapter 19 for defined terms.

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(Company secretary)

Date: 27/06/2019

Print name: Stuart Jones

== == == == ==

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Add the following:		
 Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 	14,871,250 – Share Purchase Plan	
 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval 	99,375,001 – Acquisition of infusion business	
 Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period 		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
<i>Subtract</i> the number of fully paid ⁺ ordinary securities cancelled during that 12 month period		
"A"	244,542,783	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	36,681,417	
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule	
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:		
Under an exception in rule 7.2		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	Nil	
Step 4: Subtract "C" from ["A" x "I placement capacity under rule 7.1	3"] to calculate remaining	
"A" x 0.15	36,681,417	
Note: number must be same as shown in Step 2		
Subtract "C"	Nil	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	36,681,417	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placem	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	244,542,783	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	24,454,278	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	Nil	

+ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

"A" x 0.10	24,454,278		
Note: number must be same as shown in Step 2			
Subtract "E"	Nil		
Note: number must be same as shown in Step 3			
<i>Total</i> ["A" x 0.10] – "E"	24,454,278		
	Note: this is the remaining placement capacity under rule 7.1A		

⁺ See chapter 19 for defined terms.





27 June 2019

Company Announcements Office Australian Securities Exchange Level 4, North Tower, 525 Collins Street MELBOURNE VIC 3000

PRIVATE PLACEMENT SHARES – CLEANSING NOTICE

BTC health Limited (ASX Code: BTC) (**Company**) has issued 67,533,874 shares at 8 cents per share (**Shares**) to sophisticated and institutional investors as part of a capital raise for \$5,402,709.92 as previously announced to the market.

In accordance with section 708A5 (e) of the *Corporations Act 2001 (Cth)* (**Corporations Act**), under which this notice is given, the company confirms that:

- 1. The Company issued the shares without disclosure to investors under Part 6D.2 of the *Corporations Act* 2001 (*Cth*) (**Corporations Act**);
- 2. As at the date of this notice, the Company has complied with:
 - a. The provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. Section 674 of the Corporations Act; and
- 3. As at the date of this notice, there is no information:
 - a. That has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - b. That investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:
 - i. The assets and liabilities, financial position and performance, profits and losses and prospects of the Company: or
 - ii. The rights and liabilities attaching to the ordinary shares of the Company,
 - To the extent to which it is reasonable for investors and their professional advisers to expect to find the information in a disclosure document.

Yours sincerely

Stuart Jones Company Secretary